DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

166
SECTION I
GENERAL PRINCIPLES
BIBLIOGRAPHY
Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms
in the cytochrome p450 cyp2c9 with warfarin dose
requirement and risk of bleeding complications. Lancet, 1999,
353:717–719.
Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency
in primaquine-sensitive erythrocytes. Science, 1956,
124:484–485.
Barrett JC, Fry B, Maller J, Daly MJ. Haploview: Analysis and
visualization of ld and haplotype maps. Bioinformatics, 2005,
21:263–265.
Beckmann JS, Estivill X, Antonarakis SE. Copy number variants
and genetic traits: Closer to the resolution of phenotypic to
genotypic variability. Nat Rev Genet, 2007, 8:639–646.
Bejerano G, Pheasant M, Makunin I, et al. Ultraconserved elements
in the human genome. Science, 2004, 304:1321–1325.
Boffelli D, Nobrega MA, Rubin EM. Comparative genomics at
the vertebrate extremes. Nat Rev Genet, 2004, 5:456–465.
Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6
genotype and inhibitors on tamoxifen metabolism: Implication
for optimization of breast cancer treatment. Clin Pharmacol
Ther, 2006, 80:61–74.
Brudno M, Do CB, Cooper GM, et al. Lagan and multi-lagan:
Efficient tools for large-scale multiple alignment of genomic
DNA. Genome Res, 2003, 13:721–731.
Burchard EG, Ziv E, Coyle N, et al. The importance of race and
ethnic background in biomedical research and clinical practice.
N Engl J Med, 2003, 348:1170–1175.
Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided
warfarin prescribing enhances the efficacy and safety of anticoagulation:
A prospective randomized controlled study. Clin
Pharmacol Ther, 2008, 83:460–470.
Cargill M, Altshuler D, Ireland J, et al. Characterization of singlenucleotide
polymorphisms in coding regions of human genes.
Nat Genet, 1999, 22:231–238.
Chanock S. Genetic variation and hematology: Single-nucleotide
polymorphisms, haplotypes, and complex disease. Semin
Hematol, 2003, 40:321–328.
Davies SM, Robison LL, Buckley JD, et al. Glutathione
S-transferase polymorphisms and outcome of chemotherapy
in childhood acute myeloid leukemia. J Clin Oncol, 2001,
19: 1279–1287.
den Heijer HM. Hyperhomocysteinaemia as a risk factor for
venous thrombosis: An update of the current evidence. Clin
Chem Lab Med, 2003, 41:1404–1407.
Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association
between alox5 promoter genotype and the response to antiasthma
treatment. Nat Genet, 1999, 22:168–170.
Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine
metabolism-clinical aspects. Pharmacol Ther,
1990, 46:377–394.
Eichelbaum M, Spannbrucker N, Dengler HJ. Proceedings: N-
oxidation of sparteine in man and its interindividual differences.
Naunyn Schmiedebergs Arch Pharmacol, 1975, 287
(Suppl): R94.
Erwin C. Legal update: Living with the genetic information
nondiscrimination act. Genet Med, 2008, 10:869–873.
Essen GGV, Rensma PL, Zeeuw DD, et al. Association between
angiotensin-conferting-enzyme gene polymorphism and failure
of renoprotective therapy. Lancet, 1996, 347:94–95.
Evans WE, Johnson JA. Pharmacogenomics: The inherited basis
for interindividual differences in drug response. Annu Rev
Genomics Hum Genet, 2001, 2:9–39.
Evans WE, McLeod HL. Pharmacogenomics—drug disposition,
drug targets, and side effects. N Engl J Med, 2003, 348:
538–549.
Evans WE, Relling MV. Moving towards individualized medicine
with pharmacogenomics. Nature, 2004, 429:464–468.
Furuta T, Shirai N, Sugimoto M, et al. Pharmacogenomics of proton
pump inhibitors. Pharmacogenomics, 2004, 5:181–202.
Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics:
The role of CYP2D6 as a predictor of drug response. Clin
Pharmacol Ther, 2008, 83:160–166.
Goldstein JA. Clinical relevance of genetic polymorphisms in
the human CYP2C subfamily. Br J Clin Pharmacol, 2001,
52:349–355.
Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the
common genetic defect in humans deficient in debrisoquine
metabolism. Nature, 1988, 331:442–446.
Goyette P, Sumner JS, Milos R, et al. Human methylenetetrahydrofolate
reductase: Isolation of cDNA, mapping and mutation
identification. Nat Genet, 1994, 7:195–200.
Grant DM, Morike K, Eichelbaum M, Meyer UA. Acetylation
pharmacogenetics. The slow acetylator phenotype is caused
by decreased or absent arylamine N-acetyltransferase in
human liver. J Clin Invest, 1990, 85:968–972.
Grossman I. Routine pharmacogenetic testing in clinical practice:
Dream or reality? Pharmacogenomics, 2007, 8:1449–1459.
Hartford CM, Dolan ME. Identifying genetic variants that contribute
to chemotherapy-induced cytotoxicity. Pharmacogenomics, 2007,
8:1159–1168.
Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of
CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine
and tacrolimus dose requirements and trough blood levels in
stable renal transplant patients. Pharmacogenetics, 2004,
14:147–154.
Henikoff S, Henikoff JG. Amino acid substitution matrices from
protein blocks. Proc Natl Acad Sci USA, 1992, 89:10915–10919.
Herrington DM, Howard TD, Hawkins GA, et al. Estrogenreceptor
polymorphisms and effects of estrogen replacement
on high-density lipoprotein cholesterol in women with coronary
disease. N Engl J Med, 2002, 346:967–974.
Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms
of the human multidrug-resistance gene: Multiple
sequence variations and correlation of one allele with P-glycoprotein
expression and activity in vivo. Proc Natl Acad Sci
USA, 2000, 97:3473–3478.
Hughes HB, Biehl JP, Jones AP, Schmidt LH. Metabolism of isoniazid
in man as related to occurrence of peripheral neuritis.
Am Rev Tuberc, 1954, 70:266–273.
Ingelman-Sundberg M, Evans WE. Unravelling the functional
genomics of the human CYP2D6 gene locus.
Pharmacogenetics, 2001, 11:553–554.
Ingle JN. Pharmacogenomics of tamoxifen and aromatase
inhibitors. Cancer, 2008, 112:695–699.
International HapMap C, Frazer KA, Ballinger DG, et al. A second
generation human haplotype map of over 3.1 million snps.
Nature, 2007, 449:851–861.
Iyer L, Das S, Janisch L, et al. UGT1A1∗28 polymorphism as a
determinant of irinotecan disposition and toxicity.
Pharmacogenomics J, 2002, 2:43–47.